It is the second trial to show an OS benefit with Keytruda when used in the adjuvant setting after the KEYNOTE-671 study in non-small cell lung cancer (NSCLC ... with MSD’s HIF-2 inhibitor ...

The updated guidelines note that patients with stage IV NSCLC who have EGFR exon 19 deletions or exon 21 L858R substitutions can receive osimertinib plus platinum doublet chemotherapy or amivantamab ...

It has been developed to target both the PD-1 and VEGF blockade in cancers and has proven itself in the clinic to do well in targeting patients with NSCLC. Especially, considering the fact that ...

Zongertinib is under FDA priority review for HER2-mutant advanced NSCLC, showing promise as a groundbreaking oral therapy. The phase 1b BEAMION LUNG-1 trial reported a 71% objective response rate and ...

An expert explained the importance of the FDA’s approval of Ensacove for patients with ALK-positive non-small cell lung cancer. Ensacove (ensartinib) has been approved by the Food and Drug ...

targeting PD-L1 and VEGF with SYN-2510, aiming to capitalize on promising immunotherapy trends. SYN-2510 shows early clinical promise in solid tumors, with plans for phase 3 trials in NSCLC and ...

More information: Ling Cai et al, High Glucose Contribution to the TCA Cycle Is a Feature of Aggressive Non–Small Cell Lung Cancer in Patients, Cancer Discovery (2025). DOI: 10.1158/2159-8290.CD ...

Bristol Myers Squibb (BMS) has secured another win for Opdivo (nivolumab), becoming the only FDA-approved PD-1 inhibitor for resectable non-small cell lung cancer NSCLC in both a neoadjuvant-only ...

Gilead had the right to opt in to develop and sell Arcus’ experimental hypoxia-inducible factor-2 alpha (HIF-2a) inhibitor, called casdatifan, once Arcus had delivered a qualifying data package.